Recognising complexity #Palbociclib Sigma randurls[1|1|,|CHEM1|]# A distinction between generalist and specialist palliative care

was drawn where staff felt there were “very specific problems that we have with individuals having exhausted our repertoire” [3:42], specifically in relation to symptom control and complex ethical issues. Examples included managing hydration and nutrition, Inhibitors,research,lifescience,medical and in exploring “when do you stop? Have we made the right decision? … they [palliative care specialists] come along and they say “yes, yes, you should withdraw that, yes you’re not helping them, that should come down, you’re just prolonging the suffering” it helps because you think well, that’s not just my decision and they are experts at this”. [2:12] Stroke staff reported that access to specialist advice was useful in providing “reassurance” [2:13] and to “support clinical decision-making” [3:24]. Discussions about involvement of specialists Inhibitors,research,lifescience,medical in this area tended not to focus on partnership

working through the addition of other, additional clinical perspectives or information. The focus was the provision of reassurance to the stroke team that appropriate decisions had been reached. This may reflect a lack of clarity about the clinical validity of specialist palliative care with regard to the needs of stroke patients: “The difficulty with that Inhibitors,research,lifescience,medical is, there’s no specialism within the specialism. [1:9]” Recognising dying Reflecting advances in palliative care theory, difficulties in identifying a precise time point or phase

when patients required palliative care were highlighted. “At the moment I’ve got four patients on our floor who’ve been unconscious Inhibitors,research,lifescience,medical for three or four days and I’m sitting with the families saying “I just don’t know”. Now, would this be a time for palliative care? Inhibitors,research,lifescience,medical I don’t think so, because they may recover, but then again they may not. [3:36]” As a consequence, decisions to formally assign a patient as requiring palliative care were “very slow in the making. Almost to the point where the patient has almost passed away when the decision [to commence palliative care] is made” [3:13]. Data on decision-making focused primarily on who made decisions and the team context of decision-making, rather than on what basis decisions were made. Responsibility Dacomitinib appeared to rest with the medical lead, although the decisions were couched in general terms, rather than an active decision to commence end of life care. “…it’s the consultant, that actually says “we’re changing direction here”. Maybe from the information we’ve given him, but it’s very often them that take the lead in “OK, it’s time to go” and we can sway that decision, but I think ultimately it’s the consultant that will say “this is the direction we’re going in”.